Bimekizumab efficacy and safety through two years in patients with moderate psoriasis: Analysis of pooled data from five phase 3/3b clinical trials. SKIN The Journal of Cutaneous Medicine, [S. l.], v. 6, n. 6, p. s67, 2022. DOI: 10.25251/skin.6.supp.67. Disponível em: https://skin.dermsquared.com/skin/article/view/1822. Acesso em: 16 apr. 2025.